Envisia

Envisia (Envisia Therapeutics, Inc.) was a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, spun out of Liquidia Technologies to apply PRINT (Particle Replication In Non-wetting Templates) particle-engineering to sustained-release ophthalmic therapeutics. Its lead candidate, ENV515 (travoprost) extended-release, was an intracameral implant intended to lower intraocular pressure in glaucoma patients for months from a single administration. The company was venture-backed by Canaan Partners, New Enterprise Associates, Morningside, and Batterson Venture Capital, and was acquired by Aerie Pharmaceuticals in October 2016. As a therapeutics company it exposes no public developer, API, or documentation surface, and its former web domains no longer resolve; this profile is retained as a VC-portfolio lead record with no API artifacts to enrich.

Envisia is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Ophthalmology.

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0
0 APIs
CompanyBiotechnologyPharmaceuticalsTherapeuticsOphthalmologyDrug DeliveryHealthcareClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/envisia: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Source (apis.yml)

apis.yml Raw ↑
aid: envisia
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/envisia.png
name: Envisia
description: Envisia (Envisia Therapeutics, Inc.) was a clinical-stage biopharmaceutical company based in Research Triangle
  Park, North Carolina, spun out of Liquidia Technologies to apply PRINT (Particle Replication In Non-wetting Templates) particle-engineering
  to sustained-release ophthalmic therapeutics. Its lead candidate, ENV515 (travoprost) extended-release, was an intracameral
  implant intended to lower intraocular pressure in glaucoma patients for months from a single administration. The company
  was venture-backed by Canaan Partners, New Enterprise Associates, Morningside, and Batterson Venture Capital, and was acquired
  by Aerie Pharmaceuticals in October 2016. As a therapeutics company it exposes no public developer, API, or documentation
  surface, and its former web domains no longer resolve; this profile is retained as a VC-portfolio lead record with no API
  artifacts to enrich.
url: https://raw.githubusercontent.com/api-evangelist/envisia/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Ophthalmology
- Drug Delivery
- Healthcare
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/envisia"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/envisia/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/envisia/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

A second provider on the same verified email joins the account you already have.